Cargando…
Extracellular vesicles as modifiers of antibody‐drug conjugate efficacy
Antibody‐drug conjugates (ADCs) are a new class of anti‐cancer drugs that consist of a monoclonal antibody, a highly potent small‐molecule cytotoxic drug, and a chemical linker between the two. ADCs can selectively deliver cytotoxic drugs to cancer cells leading to a reduced systemic exposure and a...
Autores principales: | Barok, Mark, Puhka, Maija, Yazdi, Narjes, Joensuu, Heikki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881363/ https://www.ncbi.nlm.nih.gov/pubmed/33613875 http://dx.doi.org/10.1002/jev2.12070 |
Ejemplares similares
-
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
por: Barok, Mark, et al.
Publicado: (2018) -
Trastuzumab emtansine: mechanisms of action and drug resistance
por: Barok, Mark, et al.
Publicado: (2014) -
Metabolic signature of extracellular vesicles depends on the cell culture conditions
por: Palviainen, Mari, et al.
Publicado: (2019) -
Urinary extracellular vesicles carry multiple activators and regulators of coagulation
por: Saraswat, Mayank, et al.
Publicado: (2022) -
Endoplasmic reticulum remains continuous and undergoes sheet-to-tubule transformation during cell division in mammalian cells
por: Puhka, Maija, et al.
Publicado: (2007)